The pharmacy benefits management industry faces a novel legal challenge as twelve independent pharmacies in Arkansas have filed what appears to be the first lawsuit under the state's recently enacted PBM accountability legislation. The action targets Express Scripts, one of the nation's largest pharmacy benefit managers, and represents a watershed moment for how states may regulate reimbursement disputes that have long favored larger corporate players.
Arkansas's decision to grant pharmacies explicit legal standing to challenge PBM payment practices reflects growing frustration with opaque reimbursement mechanisms that have squeezed independent pharmacy margins for years. The law essentially creates a new enforcement avenue that bypasses traditional regulatory channels, empowering individual businesses to pursue remedies for what they contend are systematic underpayments. This represents a meaningful departure from the status quo, where pharmacies have historically lacked practical recourse against PBM reimbursement decisions.
Why This Matters for Health System Leadership
For health system executives and pharmacy directors, this development carries significant implications across multiple fronts. First, it signals that the political and legal environment surrounding PBM practices is shifting. States increasingly view PBM regulation as a priority, and successful litigation in Arkansas could embolden other states to adopt similar enforcement mechanisms. Health systems that rely on independent pharmacy networks—particularly in rural areas—should anticipate potential disruptions if independent pharmacies face financial stress or exit markets entirely.
Second, the lawsuit highlights ongoing tensions in drug supply chain economics that ultimately affect health system costs. When PBMs compress independent pharmacy reimbursements, it can limit patient access to pharmacy services and reduce negotiating leverage for health systems themselves. The litigation may force greater transparency into PBM payment methodologies, potentially benefiting hospital systems that have their own pharmacy operations or preferred network arrangements.
Third, health system procurement teams should monitor this case for precedent-setting outcomes. If Arkansas pharmacies prevail in demonstrating systematic underpayment, it could justify similar litigation in other states or create pressure for legislative action at the federal level. This could reshape PBM contracting dynamics more broadly, potentially reducing the discount leverage that PBMs currently enjoy in negotiations.
For PBM vendors and pharmacy technology providers, the lawsuit underscores the need for enhanced transparency and documentation systems. PBMs defending against underpayment claims will need robust data demonstrating that reimbursement calculations follow stated methodologies consistently. This could accelerate demand for blockchain-based or otherwise auditable reimbursement tracking systems.
The Arkansas case also raises questions about whether current federal regulatory frameworks adequately address PBM accountability. The fact that states feel compelled to create their own enforcement mechanisms suggests gaps in oversight that could eventually attract congressional attention. Health system leaders should consider whether federal legislation addressing PBM transparency and reimbursement practices might eventually supersede state-level approaches.
Independent pharmacies represent critical infrastructure in rural and underserved areas where health systems often struggle to maintain adequate medication access. Litigation that protects independent pharmacy viability indirectly supports health system operations in these regions. Conversely, if PBM reimbursement practices drive independent pharmacies out of business, health systems may face increased pressure to expand their own pharmacy operations or rely more heavily on mail-order alternatives.
As this lawsuit progresses, health system leaders should track developments closely and consider whether their own PBM contracts adequately protect against similar disputes. The outcome could reshape pharmacy economics across the entire healthcare system for years to come.
Reporting basis: healthcaredive.com. Analysis by the HTC editorial desk.